was finely minced and single cell suspensions were fractionated over Ficoll-Hypaque gradients. Cells isolated by this technique usually were 99% positive for the CD2 antigen, as analyzed by flow cytometry.
Thymocyte Cultures. Cells were resuspended in RPMI 1640, supplemented with 2% heat-inactivated FCS, 2 MM L-glutamine, 50 AM 2-ME and antibiotics . 1-2 x 10 5 cells in 200 AI medium were added per well in 96-well flat-bottomed plates . During the last 4 h of the 96-h culture, [sH] thymidine (sp act 60 Ci/mmol, 1 PCi/well) was added. The cells were harvested by filtration and radioactivity was counted by scintillation spectrophotometry . Peripheral blood T lymphocytes were purified as described previously (12) .
Reagents. Antibody to the IL-2-R was purchased from Becton Dickinson & Co ., Mountain View, CA . This antibody inhibits the binding of IL-2 and has similar reactivity as anti-Tac . Human rIL-2 was kindly provided by Cetus Corp ., Palo Alto, CA .
Results
Initially we found that human rBSF-2/IL-6 had growth-promoting activity on PHA-activated thymocytes from (C3H/Hej) mice, which are commonly used in the lymphocyte-activating factor assay to detect IL-1 activity . Subsequently we prepared human thymocytes (?99% CD2+) from normal thymus to determine whether they also responded to BSF-2/IL-6 . rBSF-2/IL-6 increased proliferation of these cells approximately sevenfold above the response induced by PHA (0 .2-0.5% wt/vol) alone. This effect was dose dependent and low doses of BSF-2/IL-6 between 0.1 and 1 U/ml still gave significant stimulation (Fig. 1) . In all of the thymocyte preparations tested, BSF-2/IL-6 consistently stimulated proliferation significantly . The magnitude of the BSF-2/IL-6 effect showed some variability, which may reflect the contamination of thymocytes with a low proportion (< 1 %) of adherent cells that are capable of producing BSF-2/IL-6 (Lotz, M ., et al ., unpublished observations). The addition of BSF-2/IL-6 alone in the absence of PHA did not result in a detectable increase in proliferation (not shown) .
The effects of BSF-2/IL-6 on mature T lymphocytes isolated from peripheral blood were then examined . In an initial series of experiments, unfractionated PBMC were stimulated with a broad range of PHA (0 .001-1%) concentrations . Under these conditions, even the use of high doses of BSF-2/IL-6 resulted in only minor, nonsignificant increases in proliferation. However, if the PBMC populations were depleted of monocytes (<_0 .5% esterase-positive) by the use of FIGURE 2 . BSF-2/IL-6 effect on proliferation of purified T lymphocytes from peripheral blood . T lymphocytes that were essentially free of monocytes were cultured for 3 d in the presence of PHA (0 .5%) and the indicated doses of BSF-2/IL-6 . Proliferation was assayed by ['Hlthymidine incorporation . Data are shown as cpm t SEM .
E-rosetting and carbonyl-iron treatment (12) , a response to exogenous BSF-2/ IL-6 was evident. Similar to the results obtained with thymocytes, at suboptimal doses of PHA (0.1-0 .5%), BSF-2/IL-6 gave a dose-dependent increase in proliferation (Fig. 2) .
The following series of experiments examined whether the proliferative action of BSF-2/IL-6 on thymocytes and T lymphocytes was mediated via the IL-2/IL-2-R pathway. To test for BSF-2/IL-6 effects on IL-2-R expression, thymocytes were cultured for 48 h in medium alone, PHA (0.5%) alone, or in the presence of both PHA and BSF-2/IL-6 (100 U/ml). The cells were stained with directly fluoresceinated antibody to the IL-2-R (P55 component) and analyzed by flow cytometry (13) . The relative proportions of cells expressing IL-2-R were 3 .6% in the control medium, 28.2% in the PHA-stimulated cells, and 33 .8% in the presence of PHA and BSF-2/IL-6 . Similar results were obtained using monocytedepleted PBMC where the relative numbers were 4.2%, 19 .6%, 19%, respectively. Cultures prepared in parallel, using identical cell populations, and supplemented with PHA and BSF-2/IL-6, showed the expected augmentation of cell proliferation . These results suggested that the BSF-2/IL-6 stimulation of T cells was not associated with an increase in IL-2-R expression . A separate approach was then used to strengthen this observation. Thymocytes were stimulated with PHA, or with combinations of PHA and IL-2 or BSF-2/IL-6 . mAb to the IL-2-R was added to these cultures and proliferation was measured after 72 h. Table  I shows that antibody to the IL-2-R at 1 ug/ml markedly inhibited the response of the cells to the combination of PHA and IL-2, whereas the proliferative response to PHA and BSF-2/IL-6 was not significantly depressed. At higher doses of antibody (10 tcg/ml), which reduced the response to PHA alone, the IL-2 effect and also most of the IL-6 effect were inhibited. Leu-12 (an anti-B cell mAb of the same subclass [IgGl] as the anti-IL-2-R antibody) used as control, did not interfere with the proliferative effect of either cytokine. Together, these observations indicate that the effect of BSF-2/IL-6 on T cell proliferation is probably not exclusively dependent on the IL-2/IL-2-R pathway. 
Discussion
These experiments have identified BSF-2/IL-6 as a novel costimulant for human thymocytes and mature T lymphocytes. IL-6 has comitogenic activity for T lymphocytes preactivated with suboptimal doses of PHA, but does not stimulate proliferation of lymphocytes in the absence of mitogen. This dependence of BSF-2/IL-6 on mitogen prestimulation is consistent with the two-signal requirement for T cell activation . IL-6 effects on T lymphocytes isolated from peripheral blood were only detectable after monocyte depletion, as these cells are capable of producing IL-6 (3). BSF-2/IL-6-mediated increases in proliferation do not appear to be mediated via increases in IL-2-R expression . In addition, doses of antibody to the IL-2-R that inhibited proliferation induced by exogenous IL-2 did not significantly affect the response to BSF-2/IL-6 response . At higher doses of antibody the IL-6 effects were significantly inhibited, although to a lesser degree than IL-2 effects. These results suggest that the IL-6 effect is not exclusively dependent on the IL-2/IL-2-R pathway. The observed effects of BSF-2/IL-6 on T lymphocytes are consistent with the expression of BSF-2/IL-6 receptors on these cells (14) and indicate that this cytokine can potentiate not only humoral but also cellular immune responses .
Summary
Growth and differentiation of thymocytes and mature T lymphocytes is regulated by cellular interactions that are in part mediated by soluble factors. We identify IL-6, formerly called B cell stimulating factor (BSF-2), IFN-,82, or hybridoma-plasmacytoma growth factor (HPGF) as a novel T cell costimulant. rIL-6 induced a six-to seven-fold increase in proliferation of human thymocytes stimulated with suboptimal doses of PHA. A similar effect with added IL-6 could be observed using peripheral blood T lymphocytes, but only if the cultures were first rigorously depleted of monocytes that release high levels of IL-6 . Analysis of the mechanism of the IL-6 effect on thymocytes and T lymphocytes showed that IL-6 did not lead to an increase in IL-2-R expression . Concentrations of antibody to IL-2-11 inhibiting IL-2 effects did not block the IL-6-induced proliferation, indicating that the IL-6 effect was relatively IL-2 independent . These results identify IL-6 as a novel costimulant of human thymocytes and mature T lymphocytes, and suggest that IL-6 is also an important regulatory of cellular immunity .
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